The majority of patients’ organisations consider pharmaceutical companies untrustworthy, according to a survey conducted by a UK-based consultancy to be released on Friday.
In spite of efforts by the industry in recent months to provide more information on clinical trials, and funding to doctors and patient groups, 55 per cent of the patient groups also said they did not believe there had been any real increase in transparency over the past year.
GlaxoSmithKline, which experienced a sharp drop in its trustworthiness rating, said:
“We believe it is imperative to earn the trust of society, not just by meeting expectations but by exceeding them.
“The patient is central to all that we do and we are determined to be more flexible and responsive to their needs.”
Latest Share price GlaxoSmithKline
LSE 1,250p -5.00
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING